Generic warfarin: Implications for clinical practice and perceptions of anticoagulation providers

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue 6, 2004, Pages 619-626

  Bongiorno, Rachel A ^b   Nutescu, Edith A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Anticoagulation providers; Bioequivalency; Generic brand; Warfarin

Indexed keywords

GENERIC DRUG; SILDENAFIL; WARFARIN;

ANTICOAGULATION; ATTITUDE; BIOEQUIVALENCE; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG COST; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG MARKETING; DRUG MONITORING; EPISTAXIS; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; HEALTH PRACTITIONER; HUMAN; INTERNATIONAL STANDARD UNIT; MANAGED CARE; NORMAL HUMAN; NURSE; OUTPATIENT DEPARTMENT; PHARMACIST; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOEMBOLISM;

ANTICOAGULANTS; DRUGS, GENERIC; ECONOMICS, PHARMACEUTICAL; HUMANS; LEGISLATION, DRUG; NURSES; PERCEPTION; PHARMACISTS; PHYSICIANS; PRESCRIPTIONS, DRUG; QUESTIONNAIRES; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WARFARIN;

EID: 11144273889     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-861503     Document Type: Conference Paper

References (26)

1. Ansell JE. Oral anticoagulant therapy - 50 years later. Arch Intern Med 1993;153:586-596
2. DeCara JM, Croze S, Falk RH. Generic warfarin. A cost-effective alternative to brand-name drug or a clinical wild card? Chest 1998;113:261-263
3. Wittkowsky AK. Generic warfarin: implications for patient care. Pharmacotherapy 1997;17:640-643
4. Meyer M, Chan K, Bolton S. Generic warfarin: implications for patient care-another view. Pharmacotherapy 1998;18:884-886
5. Benson SR, Vance-Bryan K. In favor of Coumadin over generic warfarin. Am J Health Syst Pharm 1998;55:727-729
6. Haines ST. Reflections on generic warfarin. Am J Health Syst Pharm 1998;55:729-733
7. FDA position on product selection for 'narrow therapeutic index' drugs. Am J Health Syst Pharm 1997;547:1630-1632
8. Benet LZ, Goyan JE. Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy 1995;15:433-440
9. Hirsh J, Dalen JE, Deykin D, et al. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108(Suppl 4):231S-246S
10. The United States Pharmacopeia Approved Drug Products and Legal Requirements, 18th ed. Rockville, MD: USP Convention, Inc.; 1998
11. Ansell JE, Hughes R. Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. Am Heart J 1996;132:1095-1100
12. Wagner JL, Dent LA. Epistaxis associated with elevation of INR in a patient switched to generic warfarin. Pharmacotherapy 2000;20:240-243
13. Pfizer Package Insert: Viagra. New York: Pfizer; 2000
14. Hope KA, Havrda DE. Subtherapeutic INR values associated with a switch to generic warfarin. Ann Pharmacother 2001;35:183-187
15. DeMonaco HJ, Irby BT. Warfarin sodium: "curiouser and curiouser!" Mass Gen Hosp Drug Ther 1997;7:1-3
16. Warfarin sodium Package Insert. Pomona, NY: Barr Laboratories; 1999
17. Apothecon Package Insert: Warfarin sodium. Princeton, NJ: Apothecon; 1999
18. Taro Pharmaceuticals Package Insert: Warfarin sodium. Hawthorne, NY: Taro Pharmaceuticals; 2001
19. Richton-Hewett S, Foster E, Apstein CS. Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital. Arch Intern Med 1988;148:806-808
20. Therapeutic equivalence of generic drugs (letter to health care practitioners). Federal Drug and Food Administration. Available at: http://www.fda.gov. Accessed January 28, 2004
21. Neutel JM, Smith DHG. A randomized crossover study to compare the efficacy and tolerability of Barr warfarin sodium to the currently available Coumadin®. Cardiovasc Rev Rep 1998;19:49-59
22. Handler J, Nguyen TT, Rush S, et al. A blinded, randomized, crossover study comparing the efficacy and safety of generic warfarin sodium to Coumadin®. Prev Cardiol 1998;4:13-20
23. Swenson CN, Fundak G. Observational cohort study of switching warfarin sodium products in a managed care organization. Am J Health Syst Pharm 2000;57:452-455
24. Weibert RT, Yeager BF, Wittkowsky AK, et al. A randomized, crossover comparison of warfarin products in the treatment of chronic atrial fibrillation. Ann Pharmacother 2000;34:981-988
25. Milligan PE, Banet GA, Waterman AD, et al. Substitution of generic warfarin for Coumadin in an HMO setting. Ann Pharmacother 2002;36:764-768
26. Witt DM, Tillman DJ, Evans CM, et al. Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program. Pharmacotherapy 2003;23:360-368